Skip to main content

Table 5 Univariate associations between demographic, clinical and GA variables and RDI < 85%

From: Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

 

RDI ≥ 85%

(N = 123)

RDI < 85%

(N = 36)

OR (95% CI)

P values

Continuous variables

    

Age (per year)

56.7 (11.20)

64.2 (11.78)

1.06 (1.02–1.10)

0.001

BMI

29.3 (6.06)

30.4 (7.07)

1.03 (0.97–1.09)

0.363

BSA

1.6 (0.13)

1.6 (0.15)

1.00 (0.06– 5.72)

0.999

Number of comorbidities

1.3 (1.57)

2.3 (2.21)

1.30 (1.06–1.59)

0.01

ADL (MOS physical health)

82.0 (21.30)

70.4 (24.99)

0.98 (0.96–0.99)

0.009

IADL

12.4 (2.84)

11.9 (2.93)

0.95 (0.84–1.07)

0.407

TUG

9.7 (2.23)

9.9 (2.19)

1.04 (0.88–1.22)

0.681

Patient self-rated KPS

90.6 (12.30)

87.2 (15.97)

0.98 (0.96–1.01)

0.185

Physician-rated KPS

95.0 (5.34)

93.5 (7.34)

0.96 (0.90–1.02)

0.184

Number of falls

 0

98 (79.0%)

26 (21.0%)

1.00

 

 1+

23 (69.7%)

10 (30.3%)

1.64 (0.69–3.87)

0.26

Categorical variables

    

Race

 Hispanic

33 (82.5%)

7 (17.5%)

1.00

 

 Non-Hispanic white

63 (78.8%)

17 (21.3%)

1.27 (0.48–3.38)

0.63

 Asian

10 (66.7%)

5 (33.3%)

2.36 (0.61–9.08)

0.21

 African-American

13 (76.5%)

4 (23.5%)

1.45 (0.36–5.80)

0.60

 Others

3 (50.0%)

3 (50.0%)

4.71 (0.78–28.41)

0.09

 Missing

1

   

ER–PR, HER-2 status

 ER+ or PR+, HER2-

83 (78.3%)

23 (21.7%)

1.00

 

 HER2+

17 (68.0%)

8 (32.0%)

1.70 (0.65–4.43)

0.28

 ER- PR- HER2-

23 (82.1%)

5 (17.9%)

0.7 8 (0.27–2.29)

0.66

Stage

 Stage I

27 (79.4%)

7 (20.6%)

1.00

 

 Stage II

65 (73.9%)

23 (26.1%)

1.36 (0.52–3.56)

0.52

 Stage III

31 (83.8%)

6 (16.2%)

0.75 (0.22–2.49)

0.63

Chemotherapy regimen

 AC-T

46 (82.1%)

10 (17.9%)

1.00

 

 TC

51 (86.4%)

8 (13.6%)

0.72 (0.26–1.98)

0.53

 AC-TH

7 (63.6%)

4 (36.4%)

2.63 (0.64–10.72)

0.18

 TCH

8 (72.7%)

3 (27.3%)

1.73 (0.39–7.68)

0.47

 Sequential A-T-C

4 (40%)

6 (60%)

6.90 (1.64–29.06)

0.009

 Other non-HER2-targeted therapy

4 (66.7%)

2 (33.3%)

2.30 (0.37–14.34)

0.37

 Other HER-2-targeted therapy

3 (50%)

3 (50%)

4.60 (0.81–26.22)

0.09

Anthracycline-containing regimen

 No

61 (81.3%)

14 (18.7%)

1.00

 

 Yes

62 (73.8%)

22 (26.2%)

1.55 (0.72–3.30)

0.26

  1. Continuous variables are presented as mean (SD) and categorical variables as N (%)
  2. GA geriatric assessment, RDI reduced dose intensity, BSA body surface area, BMI body mass index, ADL Activities of Daily Living, MOS Medical Outcome Study Physical Heath Scale, IADL Instrumental Activities of Daily Living, TUG Timed Up and Go, KPS Karnofsky Performance Status, TC docetaxel plus cyclophosphamide, AC-T doxorubicin plus cyclophosphamide followed by paclitaxel, TCH docetaxel, carboplatin and trastuzumab, AC-TH doxorubicin plus cyclophosphamide followed by paclitaxel plus trastuzumab, A-T-C sequential doxorubicin, paclitaxel and cyclophosphamide
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us